Kura Oncology, Inc. (KURA)
12.40
+0.51
(+4.29%)
USD |
NASDAQ |
Aug 24, 16:00
13.12
+0.72
(+5.81%)
After-Hours: 20:00
Kura Oncology Enterprise Value : 608.46M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 608.46M |
| August 21, 2026 | 563.09M |
| August 20, 2026 | 547.08M |
| August 19, 2026 | 620.02M |
| August 18, 2026 | 602.23M |
| August 17, 2026 | 508.83M |
| August 14, 2026 | 471.47M |
| August 13, 2026 | 402.98M |
| August 12, 2026 | 389.63M |
| August 11, 2026 | 388.74M |
| August 10, 2026 | 381.63M |
| August 07, 2026 | 356.72M |
| August 06, 2026 | 330.92M |
| August 05, 2026 | 323.81M |
| August 04, 2026 | 347.82M |
| August 03, 2026 | 322.92M |
| July 31, 2026 | 306.91M |
| July 30, 2026 | 333.59M |
| July 29, 2026 | 299.79M |
| July 28, 2026 | 333.59M |
| July 27, 2026 | 408.31M |
| July 24, 2026 | 429.66M |
| July 23, 2026 | 435.00M |
| July 22, 2026 | 443.01M |
| July 21, 2026 | 474.14M |
| Date | Value |
|---|---|
| July 20, 2026 | 455.46M |
| July 17, 2026 | 471.47M |
| July 16, 2026 | 474.14M |
| July 15, 2026 | 513.28M |
| July 14, 2026 | 505.27M |
| July 13, 2026 | 475.92M |
| July 10, 2026 | 523.95M |
| July 09, 2026 | 579.99M |
| July 08, 2026 | 583.55M |
| July 07, 2026 | 571.99M |
| July 06, 2026 | 487.48M |
| July 02, 2026 | 492.82M |
| July 01, 2026 | 464.35M |
| June 30, 2026 | 481.26M |
| June 29, 2026 | 417.18M |
| June 26, 2026 | 410.97M |
| June 25, 2026 | 363.03M |
| June 24, 2026 | 386.11M |
| June 23, 2026 | 364.81M |
| June 22, 2026 | 363.03M |
| June 18, 2026 | 324.87M |
| June 17, 2026 | 292.91M |
| June 16, 2026 | 277.82M |
| June 15, 2026 | 290.25M |
| June 12, 2026 | 246.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 74.26M |
| Fortress Biotech, Inc. | -3.710M |
| Syndax Pharmaceuticals, Inc. | 1.786B |
| Spero Therapeutics, Inc. | 21.92M |
| Gossamer Bio, Inc. | 68.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -68.33M |
| Revenue (Quarterly) | 20.87M |
| Total Expenses (Quarterly) | 89.20M |
| EPS Diluted (Quarterly) | -0.769 |
| Gross Profit Margin (Quarterly) | 97.07% |
| Profit Margin (Quarterly) | -327.3% |
| Earnings Yield | -27.11% |
| Normalized Earnings Yield | -27.11 |